Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
There have been several attempts to clearly define surrogate endpoints for prostate cancer-specific survival that could be used to shorten the length of clinical trials investigating the merits of specific forms of treatment for prostate cancer. A new analysis of data from the 1,554-patient RTOG 92-02 trial has further explored two such possibilities.
Filed under: Drugs in development, Management, Treatment | Tagged: endpoint, surrogate, survival | Leave a Comment »
Reports presented this morning address: Diet and risk for prostate cancer among Jamaican males Diagnostic markers and low risk prostate cancer PSA-expression in cells from bone marrow aspirates and bone marrow biopsy specimens
Filed under: Diagnosis, Prevention, Risk | Tagged: aspirate, biopsy, bone marrow, diet, Jamaicans, PSA, risk, screening | Leave a Comment »
The “New” Prostate Cancer InfoLink has seen a couple of statements from members of the financial community in the last few days that could mislead the unwary into believing that Dendreon’s investigational immunotherapeutic agent, sipuleucel-T (Provenge), has already demonstrated a statistically significant survival benefit in its most recent Phase III clinical trial (the IMPACT trial)
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
We have identified a total of eight new reports today, of which three are particularly interesting, dealing with: Pelvic floor stimulation and biofeedback in the early recovery of continence post-surgery Adjuvant radiation therapy in men with lymph node-positive prostate cancer after radical prostatectomy The so-called “urinary flare syndrome” 16-24 months after permanent seed implant brachytherapy [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant radiation therapy, biofeedback, brachytherapy, continence, pelvic floor stimulation, positive lymph nodes, surgery, urinary flare syndrome | Leave a Comment »
… come rumors that Bernard Madoff (with the money) … Ponzi schemer extraordinaire … “may be stricken with prostate cancer.”
Filed under: Uncategorized | Comments Off
The “New” Prostate Cancer InfoLink is pleased to announce that Andrew Vickers, PhD, a specialist in biostatistics and research methodology, has accepted an invitation to join the Scientific Advisory Board of The “New” Prostate Cancer InfoLink.
Filed under: About Us | Tagged: Andrew Vickers, scientific advisory board | Comments Off
The “New” Prostate Cancer InfoLink does not normally make specific reference to individual clinical “centers of excellence” for prostate cancer. However, we are fully willing to pass on the statements of other independent third parties.
Filed under: Uncategorized | Tagged: centers of excellence | Comments Off
We have dealt separately with a study on predictors of response to sildenafil (Viagra) following radiation therapy. Other major news reported today deals with: Incidence, morbidity, and mortality of prostate cancer among men of West African ancestry Risks associated with using folate supplements Combination of ADT with EBRT in treatment of intermediate risk prostate cancer
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: African-Americans, Afro-Caribbeans, biopsy cores, folate, Her2/neu, incidence, morbidity, mortality, radiation, risk, West Africans | Leave a Comment »
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra) are now used regularly as a means to treat patients with erectile dysfunction (ED) following radiation therapy (RT) for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ED, erectile dysfunction, radiation therapy, sildenafil | 6 Comments »
Many clinicians and their patients use the so-called Kattan nomograms to help make decisions about outcomes following use of certain types of prostate cancer treatment. Apparently these prediction tools have also become known in at least some circles as “Prostagram” data. (This is the first time The “New” Prostate Cancer InfoLink has ever come across [...]
Filed under: Management, Treatment | Tagged: accuracy, actual, correlation, Kattan nomogram, outcome, prediction, Prostagram | 3 Comments »
Science Daily has now provided more detailed information (and a more accurate perspective) on the study by Draisma et al., entitled, “Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.” As of 9:10 am EST this morning, the actual content of this article is still not available on line.
Filed under: Diagnosis, Management, Risk | Tagged: lead time, over-diagnosis, screening | 10 Comments »
Reports today deal with: 5α-Reductase inhibitors and other agents in prevention of prostate cancer Expansion of patient eligibility for an Ablatherm HIFU trial in the USA Osteoprotegerin in development and progression of bone metastases Chemo-immunotherapy for treatment of metastatic disease
Filed under: Drugs in development, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: 5-ARIs, 5α-reductase inhibitors, chemo-immunotherapy, HIFU, high-intensity focuse ultrasound, osteoprotegerin, Prevention | Leave a Comment »
… is entitled, “Time is a Trickster When Cancer Runs the Clock.”
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings | Leave a Comment »
Many readers will have seen or heard a news item this evening about the dangers of “over-diagnosis” of prostate cancer. If you didn’t, here’s a link to the ABC News story.
Filed under: Diagnosis, Risk | 4 Comments »
Over the past couple of years, Baker and colleagues at the University of Leicester in England have developed and “operationalized” what appears to be a relatively sophisticated survey system to rate patient and spouse/partner/caregiver experiences from initial assessment of risk for prostate cancer through post-treatment follow-up. The “New” Prostate Cancer InfoLink thinks that a similar [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: patient experience, quality of care, survey, UK | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site